LAKE OSWEGO, Oregon (TheStreet) -- Galena Biopharma's breast cancer vaccine NeuVax will fail when results of a phase III clinical trial are eventually announced in three years or so. I can boldy predict NeuVax's failure this far in advance because Galena is making the same mistakes and taking the same sloppy shortcuts that Keryx Pharmaceuticals did with its colon cancer drug perifosine.